Skip to main content
Equibles
SGRY logo

SGRY · Surgery Partners, Inc.

Track SGRY — free

Use SGRY with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SGRY

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$15.03 -0.16 (-1.05%) At close · Aug 14
Market Cap
$1.97B
Shares
130.92M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.03 Open$15.05 Day$14.92–15.50 52W close$11.49–23.84 Avg vol 30d1.7M Short int13.5M · 10.3% float · 8.9d Short vol54% Last earningsAug 10, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 15, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −1%
      below
      Price vs 50-day avg −3%
      below
      RSI (14) 46
      neutral
      MACD trend Negative
      52-week position 29%
      mid-range
      Volume (OBV) Bullish div.
      accumulating
      Momentum
      relative strength
      Very Weak
      1-month return −6%
      trailing
      6-month return −3%
      trailing
      YTD return −3%
      this year
      Relative strength −17%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $16 › 200d $15 — 50d above 200d
      Institutional flow Accumulating
      +1% holders QoQ · +37 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      10.34% of float · ▼ -8.6% MoM · 8.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      186 holders — mid 3-yr range
      Squeeze score 63
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +19%
      Y/Y
      EPS growth +54%
      Y/Y
      Free cash flow $195.6M
      Buyback $200.0M
      authorized
      Balance sheet $3.5B
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 48%
      annualized · 1-yr
      Max drawdown −52%
      past year
      ATR 5.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 10, 2026
      Full year 2026
      Revenues $3.35B – $3.45B
      Adjusted EBITDA Non-GAAP at least $530M
      2026 Full Year
      Adjusted EBITDA at least $530M
      Organic Adjusted EBITDA Growth at least 4.2%
      Same-Facility Revenue Growth at least 3%
      Prior guidance period ended · from the 8-K filed Nov 10, 2025
      Revenue · Full year 2025 $3.28B – $3.3B
      Adjusted EBITDA · Full year 2025 $535M – $540M
      Guided vs delivered · last 2 settled
      Revenue Full year 2025
      guided $3.28B – $3.3B
      $3.31B Beat +0.6%
      Net revenue full year 2024
      guided at least $3.05B
      $3.11B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 5 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −1% Neutral
      Price vs 50-day avg
      −3% Neutral
      RSI (14)
      46 Neutral
      MACD trend
      Negative Bearish
      52-week position
      29% Neutral
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $16 › 200d $15 — 50d above 200d
      Institutional flow Accumulating
      +1% holders QoQ · +37 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      10.34% of float · ▼ -8.6% MoM · 8.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      186 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $11 Now $15 · 29% Range high $24
      vs 200-day avg -1% vs 50-day avg -3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      2026 Projected Adjusted EBITDA (Idaho Falls Market) non-GAAP $116M FY2026 —
      2026 Projected Revenue (Idaho Falls Market) $765M FY2026 —
      Adjusted EBITDA Excluding Idaho Falls Market non-GAAP $98.3M Q2 FY2026 —
      Adjusted EBITDA margin non-GAAP 13.7% Six Months Ended June 30, 2026 —
      Adjusted EBITDA Margin Excluding Idaho Falls Market non-GAAP 14.9% Q2 FY2026 —
      Adjusted EBITDA related to unconsolidated affiliates non-GAAP $32.8M Six Months Ended June 30, 2026 —
      Adjusted net income per share attributable to common stockholders - Basic non-GAAP $0.07 Six Months Ended June 30, 2026 —
      Adjusted net income per share attributable to common stockholders - Diluted non-GAAP $0.07 Six Months Ended June 30, 2026 —
      Borrowing capacity under revolving credit facility $617.8M As of June 30, 2026 —
      Case growth 0.8% Six Months Ended June 30, 2026 —
      Case growth (days adjusted) 0.8% Six Months Ended June 30, 2026 —
      Cases 325,577 Six Months Ended June 30, 2026 —
      Idaho Falls Market Adjusted EBITDA non-GAAP $26.9M Q2 FY2026 —
      Idaho Falls Market Finance Leases $288M As of 6/30/26 —
      Idaho Falls Market Other Long-Term Debt $54M As of 6/30/26 —
      Idaho Falls Market Revenue $188.8M Q2 FY2026 —
      New Physician Recruits 190 Q2 FY2026 —
      Number of consolidated surgical facilities as of the end of period 120 As of June 30, 2026 —
      Number of surgical facilities as of the end of period 178 As of June 30, 2026 —
      Number of work days in the period 127 Six Months Ended June 30, 2026 —
      Revenue Excluding Idaho Falls Market non-GAAP $660.1M Q2 FY2026 —
      Revenue growth (days adjusted) 4.9% Six Months Ended June 30, 2026 —
      Same-Facility Net Revenue Growth 5% Q2 FY2026 —
      Same-Facility Rate Growth 4.8% Q2 FY2026 —
      Same-facility Revenue per case $5,029 Six Months Ended June 30, 2026 —
      Same-Facility Surgical Cases Growth 0.3% Q2 FY2026 —
      Same-facility cases growth 0.6% first quarter —
      Same-facility revenues growth 4.4% first quarter —
      Total net debt to EBITDA ratio non-GAAP 4.3 end of the first quarter —
      Leverage calculated using consolidated debt from balance sheet divided by Adjusted EBITDA, befor non-GAAP 4.9 the fourth quarter —
      ratio of total net debt to EBITDA non-GAAP 4.3 the fourth quarter —
      Same-facility cases 3.4% the full year —
      Surgical cases -2.1% the fourth quarter —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SGRY
      Surgery Partners, Inc.
      this stock
      		$1.97B -2.7% +19.3% — 10.3%
      HCA
      HCA Healthcare, Inc.
      		 $89.77B -13.3% +7.1% 13.9 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      		 $30.87B -4.4% — — 0.0%
      THC
      Tenet Healthcare Corp
      		 $21.57B +34.8% +0.9% 10.3 4.0%
      FMS
      Fresenius Medical Care AG
      		 $12.65B -0.2% +5.9% — 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      186
      % held
      121.0%
      Net QoQ
      -3.7M sh
      Top holder
      Bain Capital Investors LLC
      Held Float
      View
      Held by Funds
      Fund positions
      207
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      13.5M
      Days to cover
      8.9d
      Change
      -1.3M sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3.0K
      Value
      $52.0K
      As of
      Jul 8, 2026
      View
      Off-Exchange
      Off-exchange %
      40.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $1.1B
      Net income (FY)
      $-77.9M
      EPS diluted
      $-0.61
      View
      Buybacks
      Authorized
      $200.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 10, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $110.8K
      Shares
      8.9K
      Filed
      Mar 16, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 10, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      SGRY -3.2% -6.0% -3.0% -2.4% -2.7%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -3.6% -10.5% -16.7% -6.3% -16.6%

      Capital returns

      Buyback program · as of Feb 26, 2026
      Authorized
      $200.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1638833 CUSIP 86881A100 13F (30d) 188 filings 182 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)